BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30411431)

  • 1. Predictive model algorithms identifying early and advanced stage ER+/HER2- breast cancer in claims data.
    Beachler DC; de Luise C; Yin R; Gangemi K; Cochetti PT; Lanes S
    Pharmacoepidemiol Drug Saf; 2019 Feb; 28(2):171-178. PubMed ID: 30411431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of an Algorithm for Identifying Patients with Hemophilia A in an Administrative Claims Database.
    Lyons J; Desai V; Xu Y; Ridgeway G; Finkle W; Solari P; Sullivan S; Lanes S
    Value Health; 2018 Sep; 21(9):1098-1103. PubMed ID: 30224115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
    Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
    Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of predictive models to identify advanced-stage cancer patients in a US healthcare claims database.
    Esposito DB; Russo L; Oksen D; Yin R; Desai VCA; Lyons JG; Verpillat P; Peñalvo JL; Lamy FX; Lanes S
    Cancer Epidemiol; 2019 Aug; 61():30-37. PubMed ID: 31128428
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Ulaner GA; Castillo R; Wills J; Gönen M; Goldman DA
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1420-1427. PubMed ID: 28456837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
    Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer.
    Asogan AB; Hong GS; Arni Prabhakaran SK
    Singapore Med J; 2017 Mar; 58(3):145-149. PubMed ID: 27029805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
    Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
    Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ReCAP: Treatment Patterns and Cost of Care Associated With Initial Therapy Among Patients Diagnosed With Operable Early-Stage Human Epidermal Growth Factor Receptor 2-Overexpressed Breast Cancer in the United States: A Real-World Retrospective Study.
    DaCosta Byfield S; Buck PO; Blauer-Peterson C; Poston SA; DaCosta Byfield S; Buck PO; Blauer-Peterson C; Poston SA
    J Oncol Pract; 2016 Feb; 12(2):159-67. PubMed ID: 26395563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
    Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
    Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does the subtype of breast cancer affect the diagnostic performance of axillary ultrasound for nodal staging in breast cancer patients?
    Vane MLG; van Nijnatten TJA; Nelemans PJ; Lobbes MBI; van Roozendaal LM; Kooreman LFS; Keymeulen KBMI; Smidt ML; Schipper RJ
    Eur J Surg Oncol; 2019 Apr; 45(4):573-577. PubMed ID: 30732971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.
    Pajenga E; Rexha T; Çeliku S; Ugrinska A; Bejtja G
    Cent Eur J Public Health; 2016 Sep; 24(3):171-175. PubMed ID: 27760283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obesity and risk of the less commonly diagnosed subtypes of breast cancer.
    Stark A; Schultz D; Kapke A; Nadkarni P; Burke M; Linden M; Raju U
    Eur J Surg Oncol; 2009 Sep; 35(9):928-35. PubMed ID: 19121564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An algorithm for the use of Medicare claims data to identify women with incident breast cancer.
    Nattinger AB; Laud PW; Bajorunaite R; Sparapani RA; Freeman JL
    Health Serv Res; 2004 Dec; 39(6 Pt 1):1733-49. PubMed ID: 15533184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating Breast Cancer Survival by Molecular Subtype in the Absence of Screening and Adjuvant Treatment.
    Munoz DF; Plevritis SK
    Med Decis Making; 2018 Apr; 38(1_suppl):32S-43S. PubMed ID: 29554464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of algorithms to identify newly diagnosed type 1 and type 2 diabetes in pediatric population using electronic medical records and claims data.
    Teltsch DY; Fazeli Farsani S; Swain RS; Kaspers S; Huse S; Cristaldi C; Nordstrom BL; Brodovicz KG
    Pharmacoepidemiol Drug Saf; 2019 Feb; 28(2):234-243. PubMed ID: 30677205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.
    Guérin A; Hao Y; Tang D; Peeples M; Fang A; Kageleiry A; Koo V; Li N; Wu EQ
    Expert Opin Pharmacother; 2016 Jun; 17(9):1189-96. PubMed ID: 27052735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
    Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
    World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.